Potential "best-in-class" therapy Oconway Biocompliant New Drug Approved Clinically

Screenshot Source: CDE.com Ocumension was founded in February 2018.
July 10, 2020, Ocon vision was officially listed on the main board of the Stock Exchange, raising approximately HK$1,553 million.
, Ocon vision entered into an exclusive license agreement with Nicox in December 2018 for exclusive rights to develop and commercialize the NCX470 in 12 other countries in Greater China, South Korea and Southeast Asia.
In a previously issued prospectus, NCX470 (OT-301) is a new chemical designed to release bima prostatin, an FDA-approved prostatin analoga, and nitric oxide (NO), which is expected to be a potential best-in-class treatment to reduce in-eye pressure in patients with glare and high eye pressure.
by combining the drug ability of nitric oxide-mediated with bima prostatin, NCX470 can activate the primary and secondary water outflow of the eye, a dual mechanism that helps to reduce in-eye pressure.
NCX470 has shown better efficacy than a single prostatin similar as a new type of second-generation nitric oxide supply type than horse prostatin.
in the completed Phase 2 clinical trials, the NCX470 showed statistical non-disadvantages and advantages over Latatin prostatin, further reducing in-eye pressure from the baseline to up to 1.4 mmHg.
safety, taking NCX470 once a day for 28 consecutive days is well-to-do and there are no serious adverse reactions associated with treatment.
NCX470 Mechanism (Photo Source: Resources) The prospectus shows that after IND approval, Ocon vision biology and Nicox plan to launch two phase 3 multi-center clinical trials of NCX470 in 2020 and plan to use data from global trials to support future applications for new drugs in China.
previously, Ocon vision biotech had undertaken extensive research and development work on NCX470, including working with Nicox to develop a global simultaneous development plan, clinical design and research program that meets the requirements of China and the United States.
glare is one of the leading causes of irreversible vision loss and blindness.
statistics, in 2018, there will be more than 130 million glare patients worldwide.
estimates that this number will reach 148 million by 2023.
important feature of this disease is elevated eye pressure.
uncontrollable increase in eye pressure can lead to optic nerve damage and vision loss, and reducing elevated eye pressure is currently the only effective way to prevent the progression of glare and loss of vision.
References: The Drug Review Center (CDE.Retrieved Oct 23,2020, from . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved Oct 22, 2020, from Source: Medical Mission Hills